Chargement en cours...
Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions
Late stage breast cancer commonly metastasises to bone and patient survival averages 2–3 years following diagnosis of bone involvement. One of the most successful treatments for bone metastases is the bisphosphonate, zoledronic acid (ZOL). ZOL has been used in the advanced setting for many years whe...
Enregistré dans:
| Publié dans: | J Bone Oncol |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7516134/ https://ncbi.nlm.nih.gov/pubmed/32995253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2020.100317 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|